Introduction
Multiple myeloma (MM) remains an incurable hematologic malignancy characterized by frequent early responses inevitably followed by treatment relapse. Until recently, few effective therapies existed. Indeed the use of alkylating agents and corticosteroids had remained the treatment of choice for almost four decades. Several novel agents for MM have now become available including the immunomodulatory drugs thalidomide and lenalidomide, as well as the proteasome inhibitor bortezomib. Each of these agents is undergoing extensive clinical evaluation in combination with other therapies to produce unprecedented response rates in newly diagnosed and relapsed MM 1 . Nevertheless, relapse remains universal and further therapeutics with broad activity are required.
In that light, numerous potential therapeutic targets have been identified. One such target is the Bcl family of proteins which confer cell survival and which are dysregulated in many malignancies including MM [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Despite the molecular heterogeneity of MM, the Bcl family member Bcl-2 has been reported to be universally expressed in MM 3 . Expression of these proteins, particularly Mcl-1, has been correlated with clinical outcomes [7] [8] [9] . In a study of 51 MM samples, 51% patients at diagnosis and 81% at relapse overexpresssed Mcl-1. Further, highest values of Mcl-1 at diagnosis were associated with the shortest event-free survival 7 . Similarly, resistance to chemotherapeutic agents has been linked to Bcl protein expression particularly with Bclx L , one of the Bcl-2 family members [13] [14] [15] . Thus, general inhibitors of the Bcl family may be more effective than those directed at Bcl-2 only. only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Knowledge that anti-apoptotic Bcl-2 family proteins are over-expressed in many cancers and contribute to tumor initiation, progression and chemotherapy resistance has spurred the development of small-molecule mimics of pro-apoptotic BH3-only proteins to overcome Bcl-2 associated resistance [16] [17] [18] [19] . Small molecule inhibitors have now been reported which induce apoptosis of cells that over-express Bcl-2 or providing proof of principle for this approach 17, 18 . Indeed pre-clinical studies of Bcl-2 and Bcl-x L specific small molecule inhibitors have recently been reported in myeloma with encouraging preclinical activity 19, 20 .
In the present study, we describe our pre-clinical work with Obatoclax (GX015-070), a novel, small-molecule antagonist of the BH3-binding groove of the Bcl-2 family of proteins 21 . Mechanistic studies suggest that GX015-070 can induce apoptosis by inhibiting the interaction between pro-and anti-apoptotic proteins, importantly, and in contrast to other inhibitors in development, including Mcl-1. In addition, GX015-070 up-regulates the pro-apoptotic BH3-only protein Bim, a natural cellular inhibitor of anti-apoptotic members. Here we describe that the inhibition of antiapoptotic Bcl-2 family proteins and the activation of pro-apoptotic Bim by GX015-070 generates single-agent mechanism-based killing of MM cell lines, as well as primary patient-derived cells. These data demonstrate that GX015-070 is a potent inhibitor of the 
Patients, Materials and Methods

Chemical compounds and biologic reagents
GX015-070 was obtained from GeminX Inc. (Malvern, PA) and dissolved in dimethyl sulfoxide (DMSO) at a stock concentration of 5 mM. For animal experiments, 30 mg of GX015-070 was dissolved in 5 mls of diluent plus 70 ml D5W to make 0.4 mg/ml solution. Human recombinant interleukin-6 (IL-6) and insulin-like growth factor-1 (IGF-1)
were obtained from R&D systems, Inc. 
Cell lines and tissue culture
All human MM cell lines (HMCLs) were maintained in Iscove Modified Dulbecco Medium (IMDM) supplemented with 5% fetal calf serum (FCS), 100 µg/ml penicillin, and 100 ug/mL streptomycin (Hyclone, Logan, UT). Peripheral blood lymphocytes (PBLs) were prepared from whole blood by Ficoll density centrifugation. Bone marrow stromal cells (BMSCs) were derived from MM patients and prepared as previously described 22 .
Briefly, mononuclear cells (MNCs) were cultured in 10 ml IMDM supplemented with 10% FCS in 100 mm tissue culture dish. Subsequent to the first week the medium was replenished every 3 days. When an adherent cell monolayer developed, the cells, which show predominantly fibroblast morphology, were trypsinized, harvested, washed, and collected by centrifugation. For the purposes of viability assays, BMSCs were plated on 96-well plates, co-culture with HMCLs are performed when the BMSCs become confluent. Bone marrow (BM) aspirates and PBLs were obtained by consent under a only. 
Viability assay
Cell viability was assessed by 3-(4,5-dimethylthiazol)-2,5-diphenyl tetrazolium (MTT) dye absorbance according to the manufacturer's instructions (Boehringer Mannheim, Mannheim, Germany). Cells were seeded in 96-well plates at a density of 20,000 cells per well (HMCLs) or 50,000 -100,000 (normal donor PBLs). Cells were incubated with or without IGF-1 (50 ng/ml) or IL-6 (10 ng/ml) where indicated and increasing concentrations of GX015-070. For each concentration of GX015-070, 10 µl aliquots of drug or DMSO diluted in culture medium was added. For drug combination studies, cells were incubated with the indicated concentration of melphalan, dexamethasone, bortezomib and/or GX015-070. Concentrations of drug that induce between 20 to 90% inhibition were selected and cells were treated with either drug (drug 1 or drug 2) as well as the combination (drug 1 and drug 2) at each dose concentration. For each dose combination, the combination index (CI) was calculated based on the following equation: 
Gene expression analysis
Cytochrome c release
Cytochrome c release apoptosis assay kit was bought from Calbiochem, San Diego, CA.
Fifty million GX015-070 treated and control cells were processed according to the kit protocol. Cytochrome c release was determined by Western blot with anti-cytochrome c antibody on proteins from the cytosolic fractions.
Apoptosis analysis of primary patient samples
For cell death analysis, MNCs were plated at a cell density of 5x10 5 cells/ml in IMDM with 15% FCS in the presence of diluted DMSO, 125, 250 and 500 nM GX015-070. 
Colony formation assays
For colony assays, 2x10 4 MNCs from BM were plated in 1 ml Methocult TM GF H4434 (StemCell Technologies Inc, Vancouver, BC) containing 1% methylcellulose and cocktail of growth factors and maintained with DMSO control or the indicated concentration of GX015-070. Seven days after plating, the number of colonies including erythroid-burstforming unit (BFU-E), granulocyte macrophage-colony-forming unit (CFU-GM), and granulocyte-erythrocyte-macrophage-megakaryocyte colony-forming unit (CFU-GEMM) were enumerated by morphological assessment, as previously described. A plating efficiency of 0.1% was routinely achieved and experiments were performed in triplicate. only.
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Xenograft mouse model
To further validate drug activity in vivo, the xenograft mouse model was prepared as previously described 24 . Briefly, 6-8 week-old female beige-nude-xid mice obtained from Frederick Cancer Research and Development Centre (Frederick, MD) were inoculated subcutaneously into the right flank with 2x10 7 KMS12-PE cells in 100 µl IMDM, together with 100 µl matrigel basement membrane matrix (Becton Dickinson, Bedford, MA).
Treatment was initiated when tumors were palpable at which time mice were randomized and treated with 4 mg/kg GX015-070 or solvent alone. Dosing was performed daily for 10 days over a 14-day period by intravenous (IV) injection. Eight to 10 mice were included in each treatment group. Caliper measurements were performed twice weekly to estimate tumor volume, using the formula: 4 /3 x (width/2) 2 x (length/2).
Mice were followed for tumor response and survival as endpoints. One-way analysis of variance was used to compare differences between vehicle and drug. For assessment of toxicity mice were weighed and total blood counts were performed weekly. only.
Results
GX015-070 inhibits the viability MM cell lines
We first examined the effect of GX015-070 on a genetically diverse panel of 16 HMCLs.
Remarkably, in 15 of 16 myeloma cell lines tested, GX015-070 induced significant reductions in cell viability in the submicromolar range with a median effective 50% growth inhibition (IC 50 ) value of 246 nM: range of 52-1100 nM ( Table 1) (Table 1) .
Given the known roles of IL-6, the BM microenvironment and, more recently IGF-1 in upregulating Bcl-2 family members thereby promoting tumor-cell survival and resistance to cytotoxic therapy in MM 28 , we next examined whether these exogenous factors could confer resistance to GX015-070. As shown in figure 1A inhibition of viability with GX015-070 was still observed when MM cell lines were grown in the presence of 50 ng/ml IGF-1 and was comparable to that of cells cultured in the absence of these growth GX015-070 demonstrated no direct toxicity to BMSCs compared to DMSO control (data not shown). The data demonstrate that GX015-070 is active as a single-agent against only.
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GX015-070 is an inhibitor of Bcl function and induces apoptosis
GX015-070 is a novel, optimized cycloprodigiosin derived, BH3 mimetic that was identified by chemical library screening and subsequently demonstrated in biochemical assays to bind to a broad-spectrum of Bcl-2 family members 16, 22 . To confirm its mechanism of action and the selectivity of GX015-070, co-immunoprecipitation studies 16 , our studies in GX015-070 sensitive MM cells failed to show inhibition of the interaction between Bcl-2 and Bax (Figure 2A ). This may reflect pharmacodynamic differences between the biochemical 16 and cell-based assays or may be MM specific.
As Mcl-1 neutralizes the pro-apoptotic function of Bim in viable MM cells, we next assessed the effects of GX15-070 on Bim protein levels. As shown in Figure 2B To confirm that GX015-070 activity is mediated by the mitochondrial pathway of apoptosis, we demonstrated that GX015-070 treatment in responsive cell lines was accompanied by cytochrome c release ( Figure 2C ). Further, cleaved caspase-3 was detected by Western blot analysis ( Figure 2C ). The results are consistent with the capacity of GX015-070 to uniquely displace activating BH3 domains from the pocket of Mcl-1 that are then free to trigger Bak oligomerization with subsequent cytochrome c release mediated apoptosis.
Expression of BCL family members in myeloma cell lines
As we predicted that differential susceptibility of HMCLs would correlate with levels of In addition to short-term cytotoxicity assays on primary myeloma cells, the potential hematological toxicity of GX015-070 was evaluated on normal PBLs and by colony formation assays. As determined by MTT assay, GX015-070 had minimal effect on PBLs viability at concentrations up to 4 µM ( Figure 4C ). However continuous exposure to GX015-070 significantly suppressed colony formation, affecting BFU-E, CFU-GEMM and CFU-GM lineages, in 8/8 samples tested ( Figure 4D ). Despite this, in vivo exposure did not induce myelosuppression in murine toxicology assays (see below).
GX015-070 inhibits the growth of primary MM cells
GX015-070 augments cytotoxicity of chemotherapy and bortezomib in MM
Bcl family members are widely known to render tumor cells resistant to induction of apoptosis by various cytotoxic drugs 29 . Modulation of this family of anti-apoptotic proteins may therefore enhance susceptibility to anti-myeloma agents and reverse only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From chemoresistance. The combined effect of GX015-070 with the anti-myeloma agents dexamethasone and melphalan was studied in paired isogenic chemosensitive and resistance cell lines. In combination with dexamethasone, GX015-070 demonstrated synergistic effect (CI<1) in the steroid-responsive cell line, MM.1S, and was able to sensitize MM.1R cells to dexamethasone ( Figure 5A ). The combination of GX015-070 and melphalan was additive (CI=1) in 8226s MM cells and minimally sensitized 8226 LR5 to melphalan ( Figure 5B ).
Finally, we evaluated the combination of GX015-070 and bortezomib. One of the undesirable effects of proteosome inhibition is the accumulation of anti-apoptotic proteins, such as Mcl-1, that may impede apoptosis 30 . We would predict that GX015-070 by inhibiting Mcl-1 may augment the activity of bortezomib. GX015-070 treatment with subsequent addition of bortezomib produced additive cytotoxic responses with a C.I.=1
( Figure 5C ). Consistent with our hypothesis, the sequencing of GX015-070 and bortezomib was critical, as less than additive responses (CI>1) were observed when the drugs were combined simultaneously or if bortezomib was added to the cells prior to GX015-070 administration. Importantly the 50-100nM concentrations of GX015-070 at which synergistic effects were observed is clinically achievable.
Evaluation of GX015-070 in vivo in a xenograft mouse model
The anti-myeloma efficacy of GX015-070 was evaluated in a subcutaneous plasmacytoma xenograft mouse model, with treatment initiated once tumors were established. At the time tumors became palpable mice were randomized to receive either vehicle or 4 mg/kg GX015-070 by IV injection for 10 days over 14 day period. The GX015-070 employed was established and recommended following formal toxicology testing by GeminX Inc. At the dose and schedule used we did not appreciate a significant difference in tumor progression between vehicle or GX015-070 treated mice only.
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To investigate the discrepancy between the in vitro and in vivo results we next assessed for target inhibition of Mcl-1 in the mice tumors. Mice bearing subcutaneous KMS12PE tumors were sacrificed 6 h after receiving the last dose of GX015-070 and tumors were harvested. Bak was immunoprecipitated from tumor lysates and the amount of co-immunoprecipitated Mcl-1 was determined on immunoblots ( Figure 6B) . In contrast to the in vitro studies, levels of Mcl-1 found to co-immunoprecipitate with Bak in GX015-070 treated cells were similar to that in vehicle treated mice demonstrating that at the administered dose, GX015-070 levels within the tumor were insufficient to inhibit Mcl-1/Bak interactions. Unfortunately, significant neurologic toxicity was observed in treated animals prohibiting further dose escalation, at least as an IV bolus. Exposed animals developed onset of agitation and hyperactivity immediately after a rapid IV injection of GX015-070 however this effect was transient. In spite of the profound neurologic effects, significant weight loss as a measure of chronic toxicity was not observed at the employed dose and despite the suppressive effects demonstrated on in vitro colony formation assay, blood counts remained normal throughout the period of treatment.
Human Phase I trials have been completed and also identified infusion related somnolence and euphoria as the most frequent side effects. Their incidence and severity has been mitigated by prolonged infusion duration from 1 h to 3 and 24 h 32 . The predicted C max after bolus injection of mice is 120ng/ml (personal communication, Jean Viallet, GeminX Pharmaceuticals, Malvern, PA) and as stated causes acute but rapidly reversible neurotoxicity and fails to achieve target inhibition at 48 hours. The rapid reversal of toxicity indicates that peak concentrations are very short lived. Human PK studies demonstrate achievable C max of 10-80ng/ml depending on the speed of infusion.
Despite these lower peak concentrations clinical activity has been observed 32 . Given these facts we believe that the sustained exposure of target cells to this inhibitor is likely only.
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Discussion
Novel therapies are still required in attempts to convert myeloma to a controllable or ultimately curable illness 1 . As such, targeting pathways critical to MM cell survival for which there are no existing therapeutics is an important goal 32, 33 . A series of studies have demonstrated the important role played by the Bcl family of proteins in sustaining MM cell survival and inhibiting cell death [7] [8] [9] [10] 12 . Overcoming this malignancy-induced barrier to apoptosis is predicted to be an attractive addition to existing therapies for MM and other cancers.
GX015-070 is a small molecule currently in Phase I/II clinical testing as a novel BH3 mimetic with purported pan-BCL activity 16 . Indeed, in studies employing chemical cross-linking to detect Mcl-1/Bak dimers in intact mitochondria, GX015-070 was found to disrupt these interactions with an IC 50 of less than 10 nM 34 . Our studies confirm that GX015-070 interferes with protein-protein interactions between Mcl-1/Bak such that the dominant influence on cell fate is switched from the anti-apoptotic to the apoptosisinducing family members with resultant release of cytochrome c and activation of caspase-3. Given the pivotal role of Mcl-1 in myeloma cells 35 , we suspect that the ability of GX015-070 to antagonize Mcl-1 will broaden the effectiveness of this compound when compared to Bcl-2 anti-sense or other Bcl antagonists that are highly selective for Bcl-2 16, 17 . This is supported by data in myeloma cells demonstrating cytotoxic responses in response to Mcl-1 but not Bcl-2 or Bcl-x L anti-sense 36 . To further account for the single agent activity of GX015-070, we also observed increased expression of the pro-only.
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We have also shown that responsiveness of cell lines to GX015-070 correlated with basal levels of bcl family members. Specifically, cells in which Bcl-x L is lacking or expressed only at very low levels are sensitive while cells that strongly express all 3 antiapoptotic proteins, Mcl-1, Bcl-2 and Bcl-x L were relatively resistant. As Bak binds with high affinity to Bcl-x L we speculate that liberation from both Mcl-1 and Bcl-x L may be required for apoptosis as has been demonstrated by Willis et al. 38 Since the IC 50 of GX015-070 for Bcl-x L is 4 fold higher than for Mcl-1 16 we would expect cells that express
Bcl-x L to be less sensitive. Further, as GX015-070 is a mimetic of pro-apoptotic BH3-only proteins we observed a direct correlation between dose response and absence or near absence of Bak protein in most HMCLs consistent with GX015-070 functioning as a competitive inhibitor of the Bak substrate. Our results suggest that GX015-070 is likely to be most efficacious as a single agent in those tumors where Bcl-x L and Bak are low, absent or inactivated and combining GX015-070 with agents that inactivate Bcl-x L may enhance and broaden its activity.
As Bim expression contributes to dexamethasone induced cell death 40, 41 and since we show here that GX015-070 up-regulates Bim, we predicted and confirmed that GX015-070 was additive to the effects of dexamethasone. Similarly, since bortezomib is reported to up-regulate Mcl-1 we find that GX015-070 further sensitizes the cells to bortezomib and that the combination of the drugs is additive. These data suggest a role for this compound in combination therapies employing drugs known to be active in myeloma. In particular, the combination of GX015-070 and bortezomib that may allow for reduced doses of bortezomib or more effective responses with full dose bortezomib and only. For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From colonies were counted after 7-9 days. Each letter represents an individual BM sample.
The results are reported as percent of vehicle treated control. KMS12-PE tumors were immediately homogenized in ice-cold lysis buffer and Bak was only.
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